Jun Wang

Dr. Jun Wang

University of California - Davis

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2023 in Cells
Verified
Journal Article
Open access
PDF file
FTFlora Tassone
Flora Tassone
DPDragana Protic
Dragana Protic
EAEmily G. Allen
Emily G. Allen
AAAlison D. Archibald
Alison D. Archibald
ABAnna Baud
Anna Baud
RHRandi Hagerman
Randi Hagerman
The premutation of the fragile X messenger ribonucleoprotein 1 (FMR1) gene is characterized by an expansion of the CGG trinucleotide repeats (55 to 200 CGGs) in the 5’ untranslated region and increased levels of FMR1 mRNA. Molecular mechanisms leading to fragile X-premutation-associated conditions (FXPAC) include cotranscriptional R-loop formations, FMR1 mRNA toxicity through both RNA gelation into nuclear foci and sequestration of various CGG-repeat-binding proteins, and the repeat-associated non-AUG (RAN)-initiated translation of potentially toxic proteins. Such molecular mechanisms contribute to subsequent consequences, including mitochondrial dysfunction and neuronal death. Clinically, premutation carriers may exhibit a wide range of symptoms and phenotypes. Any of the problems associated with the premutation can appropriately be called FXPAC. Fragile X-associated tremor/ataxia syndrome (FXTAS), fragile X-associated primary ovarian insufficiency (FXPOI), and fragile X-associated neuropsychiatric disorders (FXAND) can fall under FXPAC. Understanding the molecular and clinical aspects of the premutation of the FMR1 gene is crucial for the accurate diagnosis, genetic counseling, and appropriate management of affected individuals and families. This paper summarizes all the known problems associated with the premutation and documents the presentations and discussions that occurred at the International Premutation Conference, which took place in New Zealand in 2023.

30 July 2014 in Journal of Neurodevelopmental Disorders
Verified
Journal Article
Open access
PDF file
JGJim Grigsby
Jim Grigsby
KCKim Cornish
Kim Cornish
DHDarren Robert Hocking
Darren Robert Hocking
CKClaudine Kraan
Claudine Kraan
JOJohn Olichney
John Olichney
JYJin-Chen Yang
Jin-Chen Yang
The fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder affecting a subset of carriers of the FMR1 (fragile X mental retardation 1) premutation. Penetrance and expression appear to be significantly higher in males than females. Although the most obvious aspect of the phenotype is the movement disorder that gives FXTAS its name, the disorder is also accompanied by progressive cognitive impairment. In this review, we address the cognitive neuropsychological and neurophysiological phenotype for males and females with FXTAS, and for male and female unaffected carriers. Despite differences in penetrance and expression, the cognitive features of the disorder appear similar for both genders, with impairment of executive functioning, working memory, and information processing the most prominent. Deficits in these functional systems may be largely responsible for impairment on other measures, including tests of general intelligence and declarative learning. FXTAS is to a large extent a white matter disease, and the cognitive phenotypes observed are consistent with what some have described as white matter dementia, in contrast to the impaired cortical functioning more characteristic of Alzheimer’s disease and related disorders. Although some degree of impaired executive functioning appears to be ubiquitous among persons with FXTAS, the data suggest that only a subset of unaffected carriers of the premutation - both female and male - demonstrate such deficits, which typically are mild. The best-studied phenotype is that of males with FXTAS. The manifestations of cognitive impairment among asymptomatic male carriers, and among women with and without FXTAS, are less well understood, but have come under increased scrutiny.

1 July 2017 in Neurobiology of Aging
Verified
Journal Article
Open access
JWJun Wang
Jun Wang
DHDavid Hessl
David Hessl
RHRandi J. Hagerman
Randi J. Hagerman
TSTony J. Simon
Tony J. Simon
FTFlora Tassone
Flora Tassone
SRSusan M. Rivera
Susan M. Rivera
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder typically affecting male premutation carriers with 55-200 CGG trinucleotide repeat expansions in the FMR1 gene after age 50. The aim of this study was to examine whether cerebellar and brainstem changes emerge during development or aging in late life. We retrospectively analyzed magnetic resonance imaging scans from 322 males (age 8-81 years). Volume changes in the cerebellum and brainstem were contrasted with those in the ventricles and whole brain. Compared to the controls, premutation carriers without FXTAS showed significantly accelerated volume decrease in the cerebellum and whole brain, flatter inverted U-shaped trajectory of the brainstem, and larger ventricles. Compared to both older controls and premutation carriers without FXTAS, carriers with FXTAS exhibited significant volume decrease in the cerebellum and whole brain and accelerated volume decrease in the brainstem. We therefore conclude that cerebellar and brainstem volumes were likely affected during both development and progression of neurodegeneration in premutation carriers, suggesting that interventions may need to start early in adulthood to be most effective.

Verified
Journal Article
Open access
PDF file
JWJun Wang
Jun Wang
Eleonora NapoliEleonora Napoli
Eleonora Napoli
KKKyoungmi Kim
Kyoungmi Kim
YMYingratana A. McLennan
Yingratana A. McLennan
RHRandi Hagerman
Randi Hagerman
CGCecilia Giulivi
Cecilia Giulivi
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder affecting subjects (premutation carriers) with a 55-200 CGG-trinucleotide expansion in the 5′UTR of the fragile X mental retardation 1 gene (FMR1) typically after age 50. As both the presence of white matter hyperintensities (WMHs) and atrophied gray matter on magnetic resonance imaging (MRI) are linked to age-dependent decline in cognition, here we tested whether MRI outcomes (WMH volume (WMHV) and brain volume) were correlated with mitochondrial bioenergetics from peripheral blood monocytic cells in 87 carriers with and without FXTAS. As a parameter assessing cumulative damage, WMHV was correlated to both FXTAS stages and age, and brain volume discriminated between carriers and non-carriers. Similarly, mitochondrial mass and ATP production showed an age-dependent decline across all participants, but in contrast to WMHV, only FADH2-linked ATP production was significantly reduced in carriers vs. non-carriers. In carriers, WMHV negatively correlated with ATP production sustained by glucose-glutamine and FADH2-linked substrates, whereas brain volume was positively associated with the latter and mitochondrial mass. The observed correlations between peripheral mitochondrial bioenergetics and MRI findings—and the lack of correlations with FXTAS diagnosis/stages—may stem from early brain bioenergetic deficits even before overt FXTAS symptoms and/or imaging findings.

29 January 2016 in Molecular Genetics and Genomics
Verified
Journal Article
Closed access
PDF file
TPThang T. Pham
Thang T. Pham
JYJun Yin
Jun Yin
JEJohn S. Eid
John S. Eid
EAEvan Adams
Evan Adams
RLRegina Lam
Regina Lam
JHJeremiah W. Hanes
Jeremiah W. Hanes

1 February 2020 in Neurobiology of Aging
Verified
Journal Article
Closed access
JWJun Wang
Jun Wang
DHDavid Hessl
David Hessl
FTFlora Tassone
Flora Tassone
KKKyoungmi Kim
Kyoungmi Kim
RHRandi J. Hagerman
Randi J. Hagerman
SRSusan M. Rivera
Susan M. Rivera